IL128701A0 - 1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives - Google Patents

1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives

Info

Publication number
IL128701A0
IL128701A0 IL12870198A IL12870198A IL128701A0 IL 128701 A0 IL128701 A0 IL 128701A0 IL 12870198 A IL12870198 A IL 12870198A IL 12870198 A IL12870198 A IL 12870198A IL 128701 A0 IL128701 A0 IL 128701A0
Authority
IL
Israel
Prior art keywords
benzofuro
tetrahydro
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
IL12870198A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL128701A0 publication Critical patent/IL128701A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL12870198A 1997-04-08 1998-04-02 1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives IL128701A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201045 1997-04-08
PCT/EP1998/002136 WO1998045297A1 (en) 1997-04-08 1998-04-02 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES__

Publications (1)

Publication Number Publication Date
IL128701A0 true IL128701A0 (en) 2000-01-31

Family

ID=8228191

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12870198A IL128701A0 (en) 1997-04-08 1998-04-02 1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives

Country Status (31)

Country Link
US (1) US6156757A (ja)
EP (1) EP1019408B1 (ja)
JP (1) JP3287577B2 (ja)
KR (1) KR100315975B1 (ja)
CN (1) CN1097053C (ja)
AP (1) AP1138A (ja)
AR (1) AR012576A1 (ja)
AT (1) ATE270294T1 (ja)
AU (1) AU727599B2 (ja)
BG (1) BG63848B1 (ja)
BR (1) BR9806263A (ja)
CA (1) CA2264598C (ja)
CZ (1) CZ290008B6 (ja)
DE (1) DE69824872T2 (ja)
EE (1) EE03691B1 (ja)
ES (1) ES2224391T3 (ja)
GE (1) GEP20022823B (ja)
HU (1) HUP0003624A3 (ja)
ID (1) ID22131A (ja)
IL (1) IL128701A0 (ja)
MY (1) MY120033A (ja)
NO (1) NO322826B1 (ja)
NZ (1) NZ334501A (ja)
PL (1) PL189549B1 (ja)
RU (1) RU2198175C2 (ja)
SK (1) SK283621B6 (ja)
TR (1) TR199900644T2 (ja)
TW (1) TW589315B (ja)
UA (1) UA52681C2 (ja)
WO (1) WO1998045297A1 (ja)
ZA (1) ZA982969B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA52681C2 (uk) * 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі
AU759199B2 (en) * 1998-10-06 2003-04-10 Janssen Pharmaceutica N.V. Tricyclic delta3-piperidines as pharmaceuticals
UA70334C2 (en) 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
CZ294532B6 (cs) * 1998-12-21 2005-01-12 Janssen Pharmaceutica N. V. Benzisoxazoly a fenony jako alfa2-antagonisté, způsob jejich přípravy a použití a farmaceutický prostředek
MXPA04000036A (es) 2001-07-05 2004-05-21 Upjohn Co Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
WO2003082825A1 (en) * 2002-04-03 2003-10-09 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
EP2210892A3 (en) * 2002-10-04 2010-10-27 Prana Biotechnology Limited Neurologically-active compounds
EP1757605A4 (en) 2004-04-12 2007-12-19 Taisho Pharmaceutical Co Ltd CYCLIC AMINE COMPOUND
WO2008050732A1 (fr) * 2006-10-23 2008-05-02 Takeda Pharmaceutical Company Limited Dérivé de l'iminopyridine et son utilisation
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
UY31781A (es) * 2008-04-23 2009-12-14 Takeda Pharmaceutical Derivados de iminopiridina y su uso
US8575186B2 (en) * 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
US9067949B2 (en) 2011-01-19 2015-06-30 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
GB201704325D0 (en) * 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570701B1 (fr) * 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
US4686226A (en) * 1985-09-03 1987-08-11 Merck & Co., Inc. Substituted benzo[b]furo- and benzo[b]thieno quinolizines
JPH0256485A (ja) * 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
UA52681C2 (uk) * 1997-04-08 2003-01-15 Янссен Фармацевтика Н.В. Похідні 1,2,3,4-тетрагідро-бензофуро[3,2,-c]піридину, спосіб їх одержання та фармацевтична композиція на їх основі

Also Published As

Publication number Publication date
CA2264598C (en) 2006-10-24
ATE270294T1 (de) 2004-07-15
US6156757A (en) 2000-12-05
AP9901650A0 (en) 1999-09-30
EP1019408B1 (en) 2004-06-30
NO322826B1 (no) 2006-12-11
EE03691B1 (et) 2002-04-15
CN1237179A (zh) 1999-12-01
PL332382A1 (en) 1999-09-13
TW589315B (en) 2004-06-01
WO1998045297A1 (en) 1998-10-15
SK283621B6 (sk) 2003-10-07
JP3287577B2 (ja) 2002-06-04
EE9900114A (et) 1999-12-15
ZA982969B (en) 1999-10-07
CN1097053C (zh) 2002-12-25
AU727599B2 (en) 2000-12-14
KR100315975B1 (ko) 2001-12-22
ES2224391T3 (es) 2005-03-01
GEP20022823B (en) 2002-10-25
CA2264598A1 (en) 1998-10-15
KR20000036076A (ko) 2000-06-26
TR199900644T2 (xx) 2000-09-21
RU2198175C2 (ru) 2003-02-10
PL189549B1 (pl) 2005-08-31
HUP0003624A3 (en) 2002-09-30
CZ290008B6 (cs) 2002-05-15
BR9806263A (pt) 2000-04-04
DE69824872T2 (de) 2005-09-01
AR012576A1 (es) 2000-11-08
AU7430798A (en) 1998-10-30
DE69824872D1 (de) 2004-08-05
NO990859L (no) 1999-09-30
NO990859D0 (no) 1999-02-23
CZ68299A3 (cs) 2000-08-16
JP2000505115A (ja) 2000-04-25
BG103213A (en) 2000-05-31
UA52681C2 (uk) 2003-01-15
EP1019408A1 (en) 2000-07-19
NZ334501A (en) 2000-06-23
HUP0003624A2 (hu) 2001-04-28
ID22131A (id) 1999-09-09
BG63848B1 (bg) 2003-03-31
AP1138A (en) 2003-01-17
MY120033A (en) 2005-08-30
SK28799A3 (en) 2001-03-12

Similar Documents

Publication Publication Date Title
IL133904A0 (en) Pyridine derivatives
ZA977687B (en) Substituted 6,5-hetero-bicyclic derivatives
HK1019597A1 (en) Substituted 6, 6-hetero-bicyclic derivatives
PL334847A1 (en) Substituted 3-heterocyclyl-benzoyl derivatives
HU9800138D0 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives
SI0921125T1 (en) 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
PL338563A1 (en) Substituted derivatives of 1,2,3,4-tetrahydronaphtalene
ZA987688B (en) 6,9-bridged erythromycin derivatives
ZA9811128B (en) 1,3,8-Triaza-spiro(4,5)decan-4-on derivatives
IL134996A0 (en) 6,11-bridged erythromycin derivatives
IL128701A0 (en) 1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives
IL130377A0 (en) Diaza-spiro¬3,5¾nonane derivatives
AU5154699A (en) 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
IL136500A0 (en) 1,4-diazacycloheptane derivatives
HRP970162A2 (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
GB9706923D0 (en) Pyridine derivatives
ZA953775B (en) 8-Amino-pyrido(1,2,3-D,E)(1,3,4) Benzoxadiazine derivatives
AU2610499A (en) 4,5,6,7-tetrahydro-thieno(3,2-c)pyridine derivatives
ZA989848B (en) 6,11-bridged erythromycin derivatives
SI1027361T1 (en) 6,11-bridged erythromycin derivatives
SI1015467T1 (en) 6,9-bridged erythromycin derivatives
ZA986137B (en) Pyridine derivatives
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
HUP9903001A3 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired